Pikdare S.p.A.

MTD Group has successfully completed the acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems (BGMs) businesses, significantly progressing in its mission to serve more diabetic patients more completely. With this acquisition, MTD: ➡️Strengthens its position as the world's #2 player by increasing production capacity to over 2.5 billion pen needles. ➡️Enriches its portfolio to better cover diabetic patients and HCPs needs adding new Pen Needles with Click Technology for an easy and secure fit, an advanced sharpening geometry with up to 6 bevels, single & dual protection for HCP’s safety and - finally - a premium BGM. These top the current Pen Needle range, which includes the thinnest and shortest pen needle (G34), BGMs and CGMs (Continuous Glucose Monitoring) offering. ➡️Reaches 3bln new consumers by entering in China & India, strengthening its presence in other key markets including, North America, France & Germany. Read more https://lnkd.in/dV3SRW7d #DiabetesCare #HealthcareInnovation #Investment #Acquisition

At MTD, our dedication revolves around transforming lives through health and wellness. Our mission transcends traditional healthcare; it's rooted in the empowerment of individuals to lead healthier, more fulfilling lives.  Our professional satisfaction comes from knowing that our work matters and that we are part of something larger than ourselves. MTD is a big and various team of dedicated professionals who share this commitment.  Our work culture emphasizes continuous learning and development, and we engage in pioneering healthcare initiatives.  Our approach is all about creating a healthier world, one person at a time, through a dynamic blend of dedication, purpose, and innovation.

The heart of our ESG strategy are people, in particular patients. We are dedicated to expanding access to therapies and maximizing treatment adherence. This commitment is especially crucial for individuals grappling with chronic diseases, who must diligently manage their health every day. Through cutting-edge solutions that transform the care experience, making it more accessible and less burdensome, we empower patients to take control of their well-being daily, doing our part to stand on the side of the healthcare systems. Discover more about our committent and ESG strategy reading the 2022 Sustainability Report: https://lnkd.in/eqkkmBSV

We are delighted to present MTD's 2022 Sustainability Report, which highlights our achievements and sets forth our upcoming goals. Our Group operates with resolute commitment, a spirit of innovation, and an unwavering dedication to sustainability. We aim to protect our global community and the environment for future generations — a legacy we are determined to uphold. Through our ESG strategy, we actively contribute to advancing multiple United Nations Sustainable Development Goals (SDGs) Explore our ESG Report for 2022: https://lnkd.in/eqkkmBSV

On #WorldHeartDay we want to raise the attention of all patients affected by #heart diseases on the importance of self-monitoring and prevention. We are aware of the fact that individuals grappling with cardiovascular illnesses frequently encounter both physical and psychological obstacles that hinder their adherence to treatment. This is why we stand daily by our patients, striving to develop innovative solutions, designed to support them in taking care of their health in the simplest, less invasive and painless way.